AbbVies PEARL-III study meets main.

AbbVie’s PEARL-III study meets main, secondary endpoints in individuals with chronic GT1b HCV infection The first detailed results from AbbVie's pivotal stage III research, PEARL-III, were presented today within the 21st Conference on Retroviruses and Opportunistic Attacks press meeting and can also be presented as a late-breaker in the meeting on March 4. PEARL-III evaluated the efficacy and security of 12 weeks of treatment with AbbVie's investigational therapy with or without ribavirin in non-cirrhotic, adult patients with chronic genotype 1b hepatitis C virus infections who were not used to treatment free ed pills .

Abbott acquires control of Veropharm for $305 million Abbott today announced that it has acquired control of Veropharm, a leading Russian pharmaceutical manufacturer. Abbott has already established a presence in Russia for 40 years and nearly, in line with its long-term dedication to growing global health care capabilities and markets, the company is focused on providing a reliable way to obtain its healthcare items to Russian patients. Through this acquisition, Abbott establishes a developing footprint in Russia through Veropharm's production facilities, which include a new manufacturing unit under construction currently. Abbott also obtains a portfolio of medications that is well aligned with its current pharmaceutical therapeutic areas of focus in women's health, central nervous system, cardiovascular and gastroenterology, while adding an offering in the field of oncology and pharmaceutical R&D features for Russia.